Cargando…

Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease

BACKGROUND: Parkinson’s disease (PD) is associated with cognitive decline through multiple mechanisms, including Alzheimer’s disease (AD) pathology and cortical Lewy body involvement. However, its underlying mechanisms remain unclear. Recently, AD-related plasma biomarkers have emerged as potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizutani, Yasuaki, Ohdake, Reiko, Tatebe, Harutsugu, Higashi, Atsuhiro, Shima, Sayuri, Ueda, Akihiro, Ito, Mizuki, Tokuda, Takahiko, Watanabe, Hirohisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576723/
https://www.ncbi.nlm.nih.gov/pubmed/37480401
http://dx.doi.org/10.1007/s00415-023-11875-z
_version_ 1785121176260968448
author Mizutani, Yasuaki
Ohdake, Reiko
Tatebe, Harutsugu
Higashi, Atsuhiro
Shima, Sayuri
Ueda, Akihiro
Ito, Mizuki
Tokuda, Takahiko
Watanabe, Hirohisa
author_facet Mizutani, Yasuaki
Ohdake, Reiko
Tatebe, Harutsugu
Higashi, Atsuhiro
Shima, Sayuri
Ueda, Akihiro
Ito, Mizuki
Tokuda, Takahiko
Watanabe, Hirohisa
author_sort Mizutani, Yasuaki
collection PubMed
description BACKGROUND: Parkinson’s disease (PD) is associated with cognitive decline through multiple mechanisms, including Alzheimer’s disease (AD) pathology and cortical Lewy body involvement. However, its underlying mechanisms remain unclear. Recently, AD-related plasma biomarkers have emerged as potential tools for predicting abnormal pathological protein accumulation. We aimed to investigate the association between AD-related plasma biomarkers and cognitive decline in PD patients. METHODS: Plasma biomarkers were measured in 70 PD patients (49 with nondemented Parkinson’s disease (PDND) and 21 with Parkinson’s disease dementia (PDD)) and 38 healthy controls (HCs) using a single-molecule array. The study evaluated (1) the correlation between plasma biomarkers and clinical parameters, (2) receiver operating characteristic curves and areas under the curve to evaluate the discrimination capacity of plasma biomarkers among groups, and (3) a generalized linear model to analyze associations with Addenbrooke’s Cognitive Examination-Revised and Montreal Cognitive Assessment-Japanese version scores. RESULTS: Plasma glial fibrillary acidic protein significantly correlated with cognitive function tests, including all subdomains, with a notable increase in the PDD group compared with the HC and PDND groups, while plasma neurofilament light chain captured both cognitive decline and disease severity in the PDND and PDD groups. Plasma beta-amyloid 42/40 and pholphorylated-tau181 indicated AD pathology in the PDD group, but plasma beta-amyloid 42/40 was increased in the PDND group compared with HCs and decreased in the PDD group compared with the PDND group. CONCLUSIONS: AD-related plasma biomarkers may predict cognitive decline in PD and uncover underlying mechanisms suggesting astrocytic pathologies related to cognitive decline in PD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11875-z.
format Online
Article
Text
id pubmed-10576723
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-105767232023-10-16 Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease Mizutani, Yasuaki Ohdake, Reiko Tatebe, Harutsugu Higashi, Atsuhiro Shima, Sayuri Ueda, Akihiro Ito, Mizuki Tokuda, Takahiko Watanabe, Hirohisa J Neurol Original Communication BACKGROUND: Parkinson’s disease (PD) is associated with cognitive decline through multiple mechanisms, including Alzheimer’s disease (AD) pathology and cortical Lewy body involvement. However, its underlying mechanisms remain unclear. Recently, AD-related plasma biomarkers have emerged as potential tools for predicting abnormal pathological protein accumulation. We aimed to investigate the association between AD-related plasma biomarkers and cognitive decline in PD patients. METHODS: Plasma biomarkers were measured in 70 PD patients (49 with nondemented Parkinson’s disease (PDND) and 21 with Parkinson’s disease dementia (PDD)) and 38 healthy controls (HCs) using a single-molecule array. The study evaluated (1) the correlation between plasma biomarkers and clinical parameters, (2) receiver operating characteristic curves and areas under the curve to evaluate the discrimination capacity of plasma biomarkers among groups, and (3) a generalized linear model to analyze associations with Addenbrooke’s Cognitive Examination-Revised and Montreal Cognitive Assessment-Japanese version scores. RESULTS: Plasma glial fibrillary acidic protein significantly correlated with cognitive function tests, including all subdomains, with a notable increase in the PDD group compared with the HC and PDND groups, while plasma neurofilament light chain captured both cognitive decline and disease severity in the PDND and PDD groups. Plasma beta-amyloid 42/40 and pholphorylated-tau181 indicated AD pathology in the PDD group, but plasma beta-amyloid 42/40 was increased in the PDND group compared with HCs and decreased in the PDD group compared with the PDND group. CONCLUSIONS: AD-related plasma biomarkers may predict cognitive decline in PD and uncover underlying mechanisms suggesting astrocytic pathologies related to cognitive decline in PD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-023-11875-z. Springer Berlin Heidelberg 2023-07-22 2023 /pmc/articles/PMC10576723/ /pubmed/37480401 http://dx.doi.org/10.1007/s00415-023-11875-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Mizutani, Yasuaki
Ohdake, Reiko
Tatebe, Harutsugu
Higashi, Atsuhiro
Shima, Sayuri
Ueda, Akihiro
Ito, Mizuki
Tokuda, Takahiko
Watanabe, Hirohisa
Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
title Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
title_full Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
title_fullStr Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
title_full_unstemmed Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
title_short Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
title_sort associations of alzheimer's-related plasma biomarkers with cognitive decline in parkinson's disease
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576723/
https://www.ncbi.nlm.nih.gov/pubmed/37480401
http://dx.doi.org/10.1007/s00415-023-11875-z
work_keys_str_mv AT mizutaniyasuaki associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease
AT ohdakereiko associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease
AT tatebeharutsugu associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease
AT higashiatsuhiro associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease
AT shimasayuri associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease
AT uedaakihiro associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease
AT itomizuki associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease
AT tokudatakahiko associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease
AT watanabehirohisa associationsofalzheimersrelatedplasmabiomarkerswithcognitivedeclineinparkinsonsdisease